Eli Lilly and Company (LLY) Financials
Eli Lilly and Company (LLY) Historical Financial Statements and Key Metrics for 1994 - 2024
Full Eli Lilly and Company financials for 1994 - 2024 are available in the
US Historical Financials dataset
All financial data is sourced direct from SEC 10-Q and 10-K filings, restatements are included.
Eli Lilly and Company Income Statements
(in $ 000,000's)
| Quarter End | Revenue | Gross Profit | Operating Income | Net Income | EBITDA | EPS |
| 2024-Sep-30 | 11,439 | 9,268 (81.0 %) | 4,434 (38.8 %) | 970 (8.5 %) | 2,248 | 1.07 |
| 2024-Jun-30 | 11,303 | 9,133 (80.8 %) | 4,304 (38.1 %) | 2,967 (26.3 %) | 4,718 | 3.28 |
| 2024-Mar-31 | 8,768 | 7,234 (82.5 %) | 2,620 (29.9 %) | 2,243 (25.6 %) | 3,211 | 2.48 |
| 2023-Dec-31 | 9,353 | 7,694 (82.3 %) | 3,078 (32.9 %) | 2,190 (23.4 %) | 3,604 | 2.31 |
| 2023-Sep-30 | 9,499 | 7,638 (80.4 %) | 450 (4.7 %) | -57 (-0.6 %) | 6,401 | -0.06 |
| 2023-Jun-30 | 8,312 | 6,505 (78.3 %) | 2,126 (25.6 %) | 1,763 (21.2 %) | 2,320 | 1.95 |
| 2023-Mar-31 | 6,960 | 5,333 (76.6 %) | 1,494 (21.5 %) | 1,345 (19.3 %) | 1,704 | 1.49 |
Full historical income statements for 1994 - 2024 is included in the
US Historical Financials dataset.
Eli Lilly and Company Balance Sheets
(in $ 000,000's)
| Quarter End | Total Assets | Total Liabilities | Total Debt | Total Equity | Cash & Equivalents |
| 2024-Sep-30 | 75,607 | 61,286 | 31,120 | 14,240 | 3,518 |
| 2024-Jun-30 | 71,875 | 58,239 | 28,892 | 13,562 | 3,364 |
| 2024-Mar-31 | 63,944 | 51,046 | 26,211 | 12,812 | 2,586 |
| 2023-Dec-31 | 64,006 | 53,143 | 25,225 | 10,772 | 2,928 |
| 2023-Sep-30 | 57,916 | 46,608 | 20,168 | 11,220 | 2,494 |
| 2023-Jun-30 | 54,814 | 43,665 | 18,820 | 11,064 | 2,829 |
| 2023-Mar-31 | 53,163 | 41,868 | 18,884 | 11,190 | 3,669 |
Full historical balance sheet data for 1994 - 2024 is included in the
US Historical Financials dataset.
Eli Lilly and Company Cash Flow Statements
(in $ 000,000's)
| Quarter End | Operating Cash Flow | Investing | Financing | Free Cash Flow |
| 2024-Sep-30 | 3,712 | -4,005 | 211 | -459 |
| 2024-Jun-30 | 1,466 | -2,199 | 1,556 | 63 |
| 2024-Mar-31 | 1,166 | -1,178 | -311 | 180 |
| 2023-Dec-31 | -312 | -2,924 | 3,545 | -1,963 |
| 2023-Sep-30 | 2,190 | -3,080 | 572 | -1,812 |
| 2023-Jun-30 | 632 | -459 | -1,033 | -204 |
| 2023-Mar-31 | 1,731 | -689 | 412 | 827 |
Full historical cash flow data for 1994 - 2024 is included in the
US Historical Financials dataset.
Eli Lilly and Company Key Valuation and Operating Metrics
| Quarter End | Market Capitalization ($ 000,000's) |
Enterprise Value ($ 000,000's) |
Price/Earnings ($ 000,000's) |
Price/Sales ($ 000,000's) |
Price/Book ($ 000,000's) |
| 2024-Sep-30 | 798,232 | 825,983 | 69.78 | 205.67 | 56.06 |
| 2024-Jun-30 | 823,756 | 849,424 | 72.88 | 69.41 | 60.74 |
| 2024-Mar-31 | 685,103 | 708,855 | 78.14 | 76.36 | 53.47 |
| 2023-Dec-31 | 553,412 | 575,819 | 59.17 | 63.18 | 51.38 |
| 2023-Sep-30 | 483,310 | 501,097 | 50.88 | -2,105.01 | 43.07 |
| 2023-Jun-30 | 421,941 | 438,067 | 50.76 | 59.83 | 38.14 |
| 2023-Mar-31 | 310,205 | 325,543 | 44.57 | 57.66 | 27.72 |
Full historical valuation and operating metrics for 1994 - 2024 are included in the
US Historical Financials dataset.